Latest news

| Friday, September 11th | 0 comments

Registration open for TreatER webcast seminar on 18 November 2020 – World’s first clinical trial with CDNF: Aiming for a breakthrough in Parkinson’s

Please register for the TreatER webinar World’s 1st CDNF clinical trial: Aiming for a breakthrough in Parkinsons on Nov 18, 2020 13:00–16:00 GMT here. After registering, you will receive a confirmation email containing information about joining the webinar. Please find the program below (time in GMT):

  Moderator: Henri Huttunen, CSO, Herantis Pharma Plc
  • 13:00 – 13:05 Opening words Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc
  • 13:05 – 13:25 Neurotrophic Factors in clinical trials – Brief look to the recent past, present and years to come. Mart Saarma, Professor, Institute of Biotechnology, University of Helsinki
  • 13:25 – 13:45 Cerebral Dopamine Neurotrophic Factor (CDNF) Potential in prevention of dopamine neuron degeneration and stimulation ofneuron regeneration. Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc
  • 13:45 – 14:00 Break(with 10 min exercise, Josefa Domingos, Specialist Physiotherapist & EPDA Board Member)
  • 14:00 – 14:45 CDNF in the first-in-human clinical trial –12-month clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s. Magnus Sjögren, Chief Medical Officer, Herantis Pharma Plc and Per Svenningsson, Principal Investigator, Karolinska University Hospital
  • 14:45 – 15:00Break (with 10 min exercise, Josefa Domingos, Specialist Physiotherapist & EPDA Board Member)
  • 15:00 – 15:20 Clinical data on the investigational drug delivery systemused for the CDNF infusionJim Baker, Head of QA/RA and Clinical Affairs, Healthcare Division, Renishaw plc
  • 15:20 – 16:00 Panel discussion on CDNF development for Parkinson’s disease 
    • Per Svenningsson, Professor, Principal Investigator, Karolinska University Hospital
    • Håkan Widner, Professor, Department of Neurology, Skåne University Hospital
    • Filip Scheperjans, Adjunct Professor of Neurology, Helsinki University Hospital
    • Juha Rinne, Professor, Turku PET Centre
    • Göran Lind, Neurosurgeon, Karolinska University Hospital
    • Paul Skinner, General Manager, Renishaw Neuro Solutions Ltd
    • Craig Cook, CEO, Herantis Pharma Plc
    • Alan Whone, Consultant Senior Lecturer in Movement DisorderUniversity of Bristol
The TreatER project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 732386.